-0.001 (-4.348%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Weak
GARP
Very Weak
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Strong
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Telephone
61.7.3219.0085
Address
Unit 4 26 Brandl Street Brisbane Technology Park Eight Mile Plains, Queensland (QLD) 4113
Description
AnteoTech Ltd. engages in the development, manufacturing, and distribution of life sciences, clinical diagnostics and bio-separations products and services. The company was founded in 1995 and is headquartered in Eight Mile Plains, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.04
Trade Value (12mth)
AU$12,457.00
1 week
0%
1 month
0%
YTD
21.05%
1 year
5.42%
All time high
0.83
EPS 3 yr Growth
-51.90%
EBITDA Margin
-832.00%
Operating Cashflow
-$6m
Free Cash Flow Return
-100.70%
ROIC
-116.80%
Interest Coverage
-125.70
Quick Ratio
2.10
Shares on Issue (Fully Dilluted)
2705m
HALO Sector
Healthcare
Next Company Report Date
01-Sep-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.03
| Date | Announcements |
|---|---|
|
28 August 25 |
Full Year Results and Business Update Presentation
×
Full Year Results and Business Update Presentation |
|
28 August 25 |
Application for quotation of securities - ADO
×
Application for quotation of securities - ADO |
|
28 August 25 |
Cleansing Notice under Section 708A
×
Cleansing Notice under Section 708A |
|
27 August 25 |
FY2025 Full Year Appendix 4E and Annual Report
×
FY2025 Full Year Appendix 4E and Annual Report |
|
27 August 25 |
FY2025 Corporate Governance Statement and Appendix 4G
×
FY2025 Corporate Governance Statement and Appendix 4G |
|
19 August 25 |
Appointment of MD & CEO and Annual Staff Review Process
×
Appointment of MD & CEO and Annual Staff Review Process |
|
19 August 25 |
Proposed issue of securities - ADO
×
Proposed issue of securities - ADO |
|
19 August 25 |
Notification of cessation of securities - ADO
×
Notification of cessation of securities - ADO |
|
15 August 25 |
Queensland Government Grant Funding Update
×
Queensland Government Grant Funding Update |
|
14 August 25 |
Full Year Results Timing & Investor Call
×
Full Year Results Timing & Investor Call |
|
12 August 25 |
Appointment of South Korean Distributor
×
Appointment of South Korean Distributor |
|
11 August 25 |
$2.59 million R&D Tax Incentive received
×
$2.59 million R&D Tax Incentive received |
|
04 August 25 |
Notification of cessation of securities - ADO
×
Notification of cessation of securities - ADO |
|
30 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
22 July 25 |
Notification of cessation of securities - ADO
×
Notification of cessation of securities - ADO |
|
21 July 25 |
Agreement for combined Anteo X product in the USA
×
Agreement for combined Anteo X product in the USA |
|
18 July 25 |
Key Technical Milestone Achieved for Ultranode
×
Key Technical Milestone Achieved for Ultranode |
|
26 June 25 |
Industry Presentation - AABC Europe 2025
×
Industry Presentation - AABC Europe 2025 |
|
16 June 25 |
Wyon AG to evaluate Ultranode
×
Wyon AG to evaluate Ultranode |
|
12 June 25 |
AnteoBind Order Received and Life Sciences Update
×
AnteoBind Order Received and Life Sciences Update |
|
10 June 25 |
Strategic Review Outcomes
×
Strategic Review Outcomes |
|
08 May 25 |
Interim CEO & MD Employment Terms
×
Interim CEO & MD Employment Terms |
|
01 May 25 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
|
01 May 25 |
Notification of cessation of securities - ADO
×
Notification of cessation of securities - ADO |
|
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
